2020
Does Reducing Drinking in Patients with Unhealthy Alcohol Use Improve Pain Interference, Use of Other Substances, and Psychiatric Symptoms?
Caniglia EC, Stevens ER, Khan M, Young KE, Ban K, Marshall BDL, Chichetto NE, Gaither JR, Crystal S, Edelman EJ, Fiellin DA, Gordon AJ, Bryant KJ, Tate J, Justice AC, Braithwaite RS. Does Reducing Drinking in Patients with Unhealthy Alcohol Use Improve Pain Interference, Use of Other Substances, and Psychiatric Symptoms? Alcohol Clinical And Experimental Research 2020, 44: 2257-2265. PMID: 33030753, PMCID: PMC8077101, DOI: 10.1111/acer.14455.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useAlcohol usePain interferenceTobacco smokingUS veteransOdds ratioPsychiatric symptomsDepressive symptomsCocaine useVeterans Aging Cohort StudyAlcohol Use Disorders Identification Test (AUDIT) questionnaireCannabis useSubstance useAging Cohort StudyAnxiety symptomsSeparate logistic regression modelsChronic pain interferenceMultisite observational studyLogistic regression modelsCohort studyInverse probability weightingNext followObservational studyPotential selection biasYears postbaseline
2015
Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy
Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, Gill M, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, van Sighem A, Samji H, Hogg RS, Rybniker J, Sabin CA, Jose S, del Amo J, Moreno S, Rodríguez B, Cozzi-Lepri A, Boswell SL, Stephan C, Pérez-Hoyos S, Jarrin I, Guest JL, Monforte A, Antinori A, Moore R, Campbell CN, Casabona J, Meyer L, Seng R, Phillips AN, Bucher HC, Egger M, Mugavero MJ, Haubrich R, Geng EH, Olson A, Eron JJ, Napravnik S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JA, Hernán MA, Systems A. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. International Journal Of Epidemiology 2015, 45: 2038-2049. PMID: 26721599, PMCID: PMC5841611, DOI: 10.1093/ije/dyv295.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyCopies/Antiretroviral Therapy Cohort CollaborationTime-varying covariatesTight control groupAdjusted hazard ratioAntiretroviral therapy regimenAIDS Research NetworkIntegrated Clinical SystemsHIV-CAUSAL CollaborationDeath eventsCohort CollaborationHazard ratioTherapy regimenRandomized trialsInverse probability weightingInclusion criteriaMortality analysisClinical treatmentAIDSTherapyDeath analysisDeathTrialsComparative effects
2012
The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study
Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS 2012, 26: 1691-1705. PMID: 22546987, PMCID: PMC3647467, DOI: 10.1097/qad.0b013e328354f497.Peer-Reviewed Original ResearchConceptsAIDS-free individualsCD4 cell countEfavirenz regimensVirologic failureVirologic outcomesCell countMore nucleoside reverseNevirapine-containing regimensTreat hazard ratiosTypes of regimensProspective observational studyHIV-CAUSAL CollaborationEffect of efavirenzEfavirenz regimenNevirapine regimenNevirapine regimensHazard ratioNucleoside reverseClinical outcomesProspective studyInverse probability weightingLower incidenceObservational studyRegimensLower mortalityImpact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries
del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA. Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries. Clinical Infectious Diseases 2012, 54: 1364-1372. PMID: 22460971, PMCID: PMC3404691, DOI: 10.1093/cid/cis203.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountCohort StudiesDeveloped CountriesDrug Therapy, CombinationEuropeFemaleHIV InfectionsHIV SeropositivityHumansImmune Reconstitution Inflammatory SyndromeIncidenceMaleMiddle AgedMycobacterium tuberculosisPneumocystis cariniiPneumonia, PneumocystisRNA, ViralTuberculosisUnited StatesViral LoadConceptsImmune reconstitution inflammatory syndromeCD4 cell countCells/μL.HIV RNA levelsHazard ratioTuberculosis incidenceCART initiationCell countAntiretroviral therapyTime-varying CD4 cell countBaseline CD4 cell countAIDS-free individualsEffects of CARTLow tuberculosis incidenceMonths of ARTReconstitution inflammatory syndromeHIV-positive patientsRNA levelsHIV-positive individualsHuman immunodeficiency virusHIV-CAUSAL CollaborationInflammatory syndromeImmunodeficiency virusInverse probability weightingPositive individuals